Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03331263 · ClinicalTrials.gov registry record · Phase 1

Single Dose CHG Pharmacokinetic Study

A Phase 1 study, sponsored by Medline Industries.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target

NCT03331263 is a Phase 1 study that has completed, run by Medline Industries. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03331263, a Phase 1 study, has completed, sponsored by Medline Industries.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

A single 2% topical application of ReadyPrep® CHG was applied on either the abdomen (Treatment-1) or the groin (Treatment-2) whereas Treatment-3 consisted of a control treatment where the same procedure as Treatment-1 and -2 was performed, but without the topical application of ReadyPrep® CHG. The treatments were separated by a wash-out of 7 calendar days.

Interventions

  • DRUG Chlorhexidine Gluconate

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2017-07-21
Est. Completion 2017-08-06
Phase Phase 1

Sponsor

Medline Industries

24 total trials

What the Registry Record Tells You About NCT03331263

The ClinicalTrials.gov registry entry for NCT03331263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medline Industries, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Chlorhexidine Gluconate is the first listed.

NCT03331263 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03331263 about?

NCT03331263 is a clinical study titled "Single Dose CHG Pharmacokinetic Study". A single 2% topical application of ReadyPrep® CHG was applied on either the abdomen (Treatment-1) or the groin (Treatment-2) whereas Treatment-3 consisted of a control treatment where the same procedure as Treatment-1 and -2 was performed, but without the topical application of ReadyPrep® CHG. The t...

What is the current status of trial NCT03331263?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-07-21. Estimated completion is 2017-08-06.

What interventions are being tested in trial NCT03331263?

The interventions under investigation include: Chlorhexidine Gluconate (DRUG).

Who is sponsoring clinical trial NCT03331263?

This trial is sponsored by Medline Industries, which has 24 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.